US Retail Drug Spending Growth Accelerates In 2019, Driven Mostly By Utilization, Not Prices
Executive Summary
Price growth for brands slowed in 2019 and rebates increased at the lowest rate since 2012, the latest CMS National Health Expenditures Report finds.
You may also be interested in...
US Rx Spending Growth Projected To Stay Modest; Will Political Debate Change?
The latest update by the US Centers for Medicare & Medicaid Services to national health care spending forecasts continues to put prescription drugs in line with – or even slightly below – overall growth rates. Of course, that likely won’t change the political attention to the issue in 2022.
Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.